Aeterna Zentaris (AEZS) and Ceapro (CRPOF) announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings held today. The transaction is subject to customary closing conditions, including Alberta court approval and applicable stock exchange approvals. Subject to obtaining all required approvals and satisfying all required conditions, the transaction is expected to close in the second quarter of 2024. Following closing, a new name for the combined company will be announced for shareholders of the combined company to consider and approve at the first annual meeting of the combined company. The combined company is expected to be listed on the Nasdaq and the TSX, subject to the receipt of all necessary approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AEZS:
- ISS Endorses Aeterna Zentaris-Ceapro Merger
- ISS recommends Aeterna Zentaris, Ceapro securityholders vote for merger
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
- Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
- Aeterna Zentaris files to sell 2.53M warrants
